Prognostic value of aerobic capacity and exercise oxygen pulse in postaortic dissection patients.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 16 10 2020
revised: 15 12 2020
accepted: 17 12 2020
pubmed: 1 1 2021
medline: 16 10 2021
entrez: 31 12 2020
Statut: ppublish

Résumé

Although recommendations encourage daily moderate activities in post aortic dissection, very little data exists regarding cardiopulmonary exercise testing (CPET) to personalize those patient's physical rehabilitation and assess their cardiovascular prognosis. We aimed at testing the prognostic insight of CPET regarding aortic and cardiovascular events by exploring a prospective cohort of patients followed-up after acute aortic dissection. Patients referred to our department after an acute (type A or B) aortic dissection were prospectively included in a cohort between September 2012 and October 2017. CPET was performed once optimal blood pressure control was obtained. Clinical follow-up was done after CPET for new aortic event and major cardio-vascular events (MCE) not directly related to the aorta. Among the 165 patients who underwent CPET, no adverse event was observed during exercise testing. Peak oxygen pulse was 1.46(1.22-1.84) mlO2/beat, that is, 97 (83-113) % of its predicted value, suggesting cardiac exercise limitation in a population under beta blockers (92% of the population). During a follow-up of 39(20-51) months from CPET, 42 aortic event recurrences and 22 MCE not related to aorta occurred. Low peak oxygen pulse (<85% of predicted value) was independently predictive of aortic event recurrence, while low peak oxygen uptake (<70% of predicted value) was an independent predictor of MCE occurrence. CPET is safe in postaortic dissection patients should be used to not only to personalize exercise rehabilitation, but also to identify those patients with the highest risk for new aortic events and MCE not directly related to aorta.

Sections du résumé

BACKGROUND BACKGROUND
Although recommendations encourage daily moderate activities in post aortic dissection, very little data exists regarding cardiopulmonary exercise testing (CPET) to personalize those patient's physical rehabilitation and assess their cardiovascular prognosis.
DESIGN METHODS
We aimed at testing the prognostic insight of CPET regarding aortic and cardiovascular events by exploring a prospective cohort of patients followed-up after acute aortic dissection.
METHODS METHODS
Patients referred to our department after an acute (type A or B) aortic dissection were prospectively included in a cohort between September 2012 and October 2017. CPET was performed once optimal blood pressure control was obtained. Clinical follow-up was done after CPET for new aortic event and major cardio-vascular events (MCE) not directly related to the aorta.
RESULTS RESULTS
Among the 165 patients who underwent CPET, no adverse event was observed during exercise testing. Peak oxygen pulse was 1.46(1.22-1.84) mlO2/beat, that is, 97 (83-113) % of its predicted value, suggesting cardiac exercise limitation in a population under beta blockers (92% of the population). During a follow-up of 39(20-51) months from CPET, 42 aortic event recurrences and 22 MCE not related to aorta occurred. Low peak oxygen pulse (<85% of predicted value) was independently predictive of aortic event recurrence, while low peak oxygen uptake (<70% of predicted value) was an independent predictor of MCE occurrence.
CONCLUSION CONCLUSIONS
CPET is safe in postaortic dissection patients should be used to not only to personalize exercise rehabilitation, but also to identify those patients with the highest risk for new aortic events and MCE not directly related to aorta.

Identifiants

pubmed: 33381882
doi: 10.1002/clc.23537
pmc: PMC7852169
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-260

Informations de copyright

© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Références

Medicine (Baltimore). 2017 Mar;96(12):e6407
pubmed: 28328839
Circ Heart Fail. 2017 Feb;10(2):
pubmed: 28159826
J Am Heart Assoc. 2017 Oct 31;6(11):
pubmed: 29089342
J Hypertens. 2012 Jul;30(7):1277-88
pubmed: 22573122
Mayo Clin Proc. 2017 Feb;92(2):228-233
pubmed: 27938891
J Am Coll Cardiol. 2010 Sep 7;56(11):845-54
pubmed: 20813282
Prog Cardiovasc Dis. 2017 Jun - Jul;60(1):11-20
pubmed: 28286137
Circulation. 1995 Nov 1;92(9 Suppl):II107-12
pubmed: 7586392
J Am Coll Cardiol. 2017 Apr 18;69(15):1937-1948
pubmed: 28408024
J Am Coll Cardiol. 2017 Jul 11;70(2):136-148
pubmed: 28683960
J Appl Physiol (1985). 1997 Mar;82(3):908-12
pubmed: 9074981
Circulation. 2014 Oct 14;130(16):e140-2
pubmed: 25311622
Scand Cardiovasc J. 2017 Apr;51(2):99-105
pubmed: 27808563
Clin Cardiol. 2015 Nov;38(11):652-9
pubmed: 26769699
Eur J Prev Cardiol. 2018 May;25(7):772-782
pubmed: 29488810
J Am Soc Echocardiogr. 2015 Jul;28(7):727-54
pubmed: 26140936
J Am Heart Assoc. 2017 Sep 25;6(9):
pubmed: 28947563
Chest. 1997 Oct;112(4):1091-101
pubmed: 9377922
J Cardiopulm Rehabil Prev. 2020 Mar;40(2):108-115
pubmed: 31478921
Am J Transplant. 2014 Jan;14(1):88-95
pubmed: 24354872
Clin Cardiol. 2021 Feb;44(2):252-260
pubmed: 33381882
J Sports Sci Med. 2018 Aug 14;17(3):339-347
pubmed: 30116106
Eur Heart J. 2014 Nov 1;35(41):2873-926
pubmed: 25173340
JAMA. 1996 Jul 17;276(3):205-10
pubmed: 8667564
J Am Heart Assoc. 2015 Jan 21;4(1):e001513
pubmed: 25609416
Int J Cardiol. 2016 Sep 15;219:271-6
pubmed: 27343419
Eur J Cardiovasc Prev Rehabil. 2009 Feb;16(1):91-5
pubmed: 19237998

Auteurs

Pascal Delsart (P)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Camille Delahaye (C)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Patrick Devos (P)

University of Lille, CHU Lille, EA 2694 - Santé publique: épidémiologie et qualité des soins, Lille, France.

Olivia Domanski (O)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Richard Azzaoui (R)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Jonathan Sobocinski (J)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1008, Lille, France.

Francis Juthier (F)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Andre Vincentelli (A)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Natacha Rousse (N)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Agnes Mugnier (A)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Jerome Soquet (J)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Valentin Loobuyck (V)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Mohamed Koussa (M)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Thomas Modine (T)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Bruno Jegou (B)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Antoine Bical (A)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Ilir Hysi (I)

Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Générale de Santé, Lens, France.

Olivier Fabre (O)

Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Générale de Santé, Lens, France.

François Pontana (F)

CHU Lille, Institut Coeur-Poumon, Lille, France.
University of Lille, CHU Lille, Inserm U1011, Lille, France.

Regis Matran (R)

CHU Lille, Institut Coeur-Poumon, Lille, France.

Claire Mounier-Vehier (C)

CHU Lille, Institut Coeur-Poumon, Lille, France.

David Montaigne (D)

CHU Lille, Department of Clinical Physiology & echocardiography, Univ. Lille, Inserm U1011-EGID, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH